HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Clinical Trial: Melflufen (not Melphalan) and dexamethasone for Relapsed/Refractory Myeloma
Posted: Nov 22, 2016
Clinical Trial: Melflufen (not Melphalan) and dexamethasone for Relapsed/Refractory Myeloma image

Melflufen is a modified version of melphalan. Multiple myeloma cells have enzymes that are overexpressed at very high levels. Melflufen is trapped at higher concentrations within diseased cells, so it is more targeted than melphalan. According to the company developing the drug, Oncopeptides AB in Sweden, melflufen has a 50-100x higher anti-tumor potency over melphalan. The new drug melflufen is now being tested with dexamethasone for patients with relapsed/refractory multiple myeloma. One of the study goals  is to use the drug for patients who have become refractory to pomalidomide and/or daratumumab. Patients will be treated with melflufen on Day 1 and then dex on days 1, 8, 15 and 22 of a 28-day cycle. To find this clinical trial on SparkCures, click here: Melflufen and Dex Clinical Trial    

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube